Condition
Prostate Adenocarcinoma Without Neuroendocrine Differentiation
Total Trials
2
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
100.0%
2 terminated out of 2 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
2Total
P 2 (2)
Trial Status
Terminated2
Clinical Trials (2)
Showing 2 of 2 trials
NCT03360721Phase 2Terminated
Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer
NCT03570476Phase 2TerminatedPrimary
Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer
Showing all 2 trials